journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lymphoma, Myeloma & Leukemia

journal
https://www.readbyqxmd.com/read/29223388/transplantation-in-the-treatment-of-primary-cutaneous-aggressive-epidermotropic-cytotoxic-cd8-positive-t-cell-lymphoma
#1
Benoit M Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss
BACKGROUND: Primary cutaneous aggressive epidermotropic cytotoxic CD8 positive T-cell lymphoma (CD8+ PCAETL) is a rare subtype of peripheral T-cell lymphoma with poor outcomes and without a standardized treatment strategy. Allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a potential curative therapy. PATIENTS AND METHODS: We conducted a retrospective case series. We identified 8 patients with the diagnosis of CD8+ PCAETL, 4 of whom also underwent allogeneic HSCT...
December 6, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29208403/efficacy-of-standard-dose-r-chop-alternating-with-r-hdac-followed-by-autologous-hematopoietic-cell-transplantation-as-initial-therapy-of-mantle-cell-lymphoma-a%C3%A2-single-institution-experience
#2
Yazeed Sawalha, Brian T Hill, Lisa A Rybicki, Danyu Sun, Robert M Dean, Deepa Jagadeesh, Betty K Hamilton, Aaron T Gerds, Ronald M Sobecks, Steven Andresen, Hien K Liu, Navneet S Majhail, Brad Pohlman, Matt E Kalaycio, Brian J Bolwell, Mitchell R Smith
BACKGROUND: Young fit patients with mantle cell lymphoma (MCL) are commonly treated with induction chemotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT). Induction regimens with modifications of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and/or incorporation of high-dose cytarabine (HDAC) appear more effective than R-CHOP alone. PATIENTS AND METHODS: We adopted a modification of the Nordic protocol using standard, rather than higher dose R-CHOP, alternating with HDAC (rituximab plus HDAC), for 3 cycles each or, for patients already treated with R-CHOP alone before referral for AHCT, an additional 2 cycles of rituximab plus HDAC...
December 2, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29196178/long-term-remissions-of-patients-with-follicular-lymphoma-grade-3-treated-with-r-chop
#3
Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L Jeffrey Medeiros, Michael J Overman, Jorge E Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S Neelapu, Luis Fayad
BACKGROUND: The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. PATIENTS AND METHODS: This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. RESULTS: The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years...
November 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29191715/vcr-cvad-induction-chemotherapy-followed-by-maintenance-rituximab-produces-durable-remissions-in-mantle-cell-lymphoma-a-wisconsin-oncology-network-study
#4
Julie E Chang, Lakeesha L Carmichael, KyungMann Kim, Christopher Peterson, David T Yang, Anne M Traynor, Jae E Werndli, Michael S Huie, Thomas A McFarland, Michael Volk, Jules Blank, Natalie S Callander, Walter L Longo, Brad S Kahl
INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND METHODS: Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2 × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses)...
November 4, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29169873/modified-hypercvad-versus-bortezomib-hypercad-in-patients-with-relapsed-refractory-multiple-myeloma
#5
Megan M Saraceni, Emma Scott, Richard T Maziarz, Matthew B Siegel, Solange Bassale, Susie Jiing, Eva Medvedova
INTRODUCTION: Multiple myeloma (MM) is an incurable plasma cell malignancy, in which aggressive relapses might require salvage cytotoxic infusional chemotherapy. Several clinical trials that reported the efficacy of bortezomib led to institutional practice changes in which vincristine was replaced with bortezomib in the modified hyperCVAD regimen, creating a new treatment regimen, named "bortezomib-hyperCAD." PATIENTS AND METHODS: We retrospectively describe the effectiveness and tolerability of 2 chemotherapy regimens among 33 patients with relapsed and/or refractory MM...
November 2, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29158114/early-relapse-for-multiple-myeloma-patients-undergoing-single-autologous-stem-cell-therapy-a-single-center-experience
#6
Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J Bahlis, Victor H Jimenez-Zepeda
INTRODUCTION: Multiple myeloma is a heterogeneous disease with diverse clinical courses and patient outcomes. Although the introduction of novel agents has improved the overall survival (OS) of multiple myeloma patients, reports have highlighted that a subset of patients persists who experience early relapse (ER) and whose prognosis is significantly poorer than that of patients with a longer therapy response. METHODS: The purpose of the present study was to understand the effect of ER on OS and identify other predictors of OS...
November 1, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29122536/a-systematic-review-of-treatments-of-relapsed-refractory-mantle-cell-lymphoma
#7
REVIEW
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson
A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched...
October 13, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29126867/allogeneic-hematopoietic-cell-transplantation-for-richter-syndrome-a-single-center-experience
#8
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Facundo E Stingo, Farhad Khimani, Mohammad Hussaini, Ernesto Ayala, Taiga Nishihori, Bijal Shah, Frederick L Locke, Javier Pinilla-Ibarz, Julio C Chavez
BACKGROUND: Recent studies have shown dismal outcomes when chronic lymphocytic leukemia progresses to Richter syndrome after patients receive ibrutinib, with a median overall survival ranging from 2.6 to 3.5 months. Published data on efficacy of allogeneic hematopoietic cell transplantation in Richter syndrome are limited to single-center case series and registry data. PATIENTS AND METHODS: We evaluated the efficacy of allogeneic transplantation in 10 patients, median age of 63 (range, 50-74) years, allografted at a median of 5 (range, 4-25) months from diagnosis of Richter syndrome...
October 12, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29102414/are-we-choosing-wisely-in-lymphoma-excessive-use-of-surveillance-ct-imaging-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-in-long-term-remission
#9
Matthew C Cheung, Nicole Mittmann, Craig C Earle, Farah Rahman, Ning Liu, Simron Singh
INTRODUCTION: The use of surveillance computed tomography (CT) imaging in patients with diffuse large B-cell lymphoma in remission is neither effective nor cost-effective. The American Society of Hematology Choosing Wisely (CW) campaign, in particular, emphasizes the lack of benefit beyond 2 years of completion of therapy. We sought to describe the real-world practice of surveillance imaging. PATIENTS AND METHODS: We used population-based health system administrative databases from Ontario, Canada...
October 9, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29102415/hereditary-hemochromatosis-manifesting-after-treatment-of-paroxysmal-nocturnal-hemoglobinuria-with-eculizumab
#10
Elizabeth Elliott, Salman Waheed, Sahr Syed, Sheila Eswaran, Stephanie Gregory, Jamile Shammo
No abstract text is available yet for this article.
October 7, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29066226/cast-nephropathy-and-deceptively-low-absolute-serum-free-light-chain-levels-resolution-of-a-challenging-case-and-systematic-review-of-the-literature
#11
Michael P Rassner, Maximilian Seidl, Ulrich Salzer, S Vincent Rajkumar, Thomas Epting, Ralph Wäsch, Elke Neumann-Haefelin, Monika Engelhardt
No abstract text is available yet for this article.
October 3, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29066162/two-states-of-myeloma-stem-cells
#12
Shmuel Yaccoby
The identity of so-called malignant stem cells in multiple myeloma has long been controversial. However, it is now appreciated that a small population of myeloma cells has a stem-like capacity for self-renewal and resides within the population of recognizable myeloma plasma cells, although whether these cells are quiescent or proliferative remains unresolved. It is also now accepted that subpopulations of myeloma plasma cells alternate bidirectionally and dynamically between immature and mature phenotypes, and both subpopulations are capable of clonogenicity in vitro and in animal models...
October 3, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29107583/outcomes-of-patients-with-relapsed-core-binding-factor-positive-acute-myeloid-leukemia
#13
Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad A Alzubaidi, Sherry A Pierce, Farhad Ravandi, Hagop M Kantarjian, Gautam Borthakur
PURPOSE: To determine the factors associated with outcomes in patients with core binding factor acute myeloid leukemia (CBF-AML) in first relapse. MATERIAL AND METHODS: We conducted a retrospective analysis of 92 patients with CBF-AML in first relapse who presented to our institution from 1990-2014. Clinical and demographic parameters were included in univariate and multivariate Cox proportional hazards regression model to predict overall survival. RESULTS: Among the 92 relapsed patients, 60 (65%) patients had inv (16) and 32 (35%) had t (8;21)...
September 25, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29097160/clinical-practice-guidelines-for-diagnosis-and-treatment-of-chronic-lymphocytic-leukemia-cll-in-the-netherlands
#14
Sabina Kersting, Suzanne I M Neppelenbroek, Hein P J Visser, Michel van Gelder, Mark-David Levin, Rogier Mous, Ward Posthuma, Hanneke M van der Straaten, Arnon P Kater
INTRODUCTION: In recent years, considerable progress has been made in the treatment of patients with chronic lymphocytic leukemia (CLL), and new potent drugs have become available. Therefore, the CLL working party revised the Dutch guidelines. Not only efficacy but also quality of life and socio-economic impact were taken into account in the formulation of treatment recommendations. MATERIALS AND METHODS: The working party discussed a set of questions regarding diagnostic tests and treatment and wrote the draft guideline...
September 25, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29103980/extranodal-marginal-zone-lymphoma-of-the-central-nervous-system
#15
REVIEW
Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A Cherry
Extranodal marginal zone lymphoma of the central nervous system (CNS EMZBL) is a rare disease. We present a review of the literature and describe its presentation, differential diagnosis, treatment options, and outcomes. Systematic search of PubMed, Medline, and Embase databases via the Ovid engine for primary articles and case reports yielded 37 unduplicated peer-reviewed articles of CNS EMZBL. We identified 69 cases in these articles and 1 unreported case at our institution, which were included for this review's analysis...
September 23, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29051078/the-role-of-radiation-in-all-stages-of-nodular-lymphocytic-predominant-hodgkin-lymphoma
#16
Bismarck Odei, Dustin Boothe, Jonathan Frandsen, Matthew M Poppe, David K Gaffney
BACKGROUND: The goal of this study was to assess the survival differences seen in early-stage and advanced-stage nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) based on treatment modality. PATIENTS AND METHODS: The National Cancer Database was queried to identify patients diagnosed with NLPHL between 2004 and 2012. Overall survival (OS) was determined using univariate and multivariate Cox regression analysis. Kaplan-Meier and log-rank analysis were used to estimate differences in OS between treatment groups...
September 23, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29100976/a-comparison-of-clofarabine-based-gclac-and-cladribine-based-clag-salvage-chemotherapy-for-relapsed-refractory-aml
#17
Benyam Muluneh, Kaitlyn Buhlinger, Allison M Deal, Joshua F Zeidner, Matthew C Foster, Katarzyna Joanna Jamieson, Jill Bates, Hendrik W Van Deventer
BACKGROUND: Salvage regimens for patients with relapsed/refractory acute myeloid leukemia (rrAML) lack comparative data for superiority. Thus, we conducted a retrospective analysis of clofarabine-based (GCLAC; granulocyte colony-stimulating factor [filgrastim], clofarabine, high-dose cytarabine) versus cladribine-based (CLAG; cladribine, cytarabine, granulocyte colony-stimulating factor [filgrastim]) regimens in rrAML. PATIENTS AND METHODS: We identified 41 consecutive patients with rrAML who had received either GCLAC or CLAG from 2011 to 2014...
September 22, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29097159/the-epidemiology-and-clinical-associations-of-stroke-in-patients-with-acute-myeloid-leukemia-a-review-of-10-972-admissions-from-the-2012-national-inpatient-sample
#18
Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman
BACKGROUND: Acute leukemia is known to confer an elevated risk of both hemorrhagic and thrombotic complications, but the development of stroke in this population is poorly characterized. This study assesses clinical and epidemiologic factors in a population of inpatients with acute myeloid leukemia (AML) and stroke. METHODS: Using the 2012 National Inpatient Sample, demographic and clinical data including age, gender, race, length of stay, in-hospital procedures, discharge diagnosis, disposition, and mortality incidence were extracted...
September 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29079283/consolidative-radiotherapy-after-autologous-stem-cell-transplantation-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
#19
Brendan G Coutu, Christopher T Wilke, Jianling Yuan, Qing Cao, Matthew R Vernon, Chung Lee, Veronika Bachanova, Kathryn E Dusenbery
INTRODUCTION: We evaluated the role of consolidative radiotherapy (RT) for patients undergoing high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). MATERIALS AND METHODS: We reviewed the medical records of 72 consecutive patients who had undergone ASCT for relapsed or refractory DLBCL at our institution from 2006 to 2014. Pretransplant conditioning consisted of HDC and total body irradiation...
September 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29051077/cellular-proliferation-by-multiplex-immunohistochemistry-identifies-high-risk-multiple-myeloma-in-newly-diagnosed-treatment-naive-patients
#20
Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M Mark
INTRODUCTION: Therapeutic options for multiple myeloma (MM) are growing, yet clinical outcomes remain heterogeneous. Cytogenetic analysis and disease staging are mainstays of risk stratification, but data suggest a complex interplay between numerous abnormalities. Myeloma cell proliferation is a metric shown to predict outcomes, but available methods are not feasible in clinical practice. PATIENTS AND METHODS: Multiplex immunohistochemistry (mIHC), using multiple immunostains simultaneously, is universally available for clinical use...
September 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
journal
journal
42898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"